



## CASE ANECDOTES, COMMENTS AND OPINIONS

### First lung and kidney multi-organ transplant following COVID-19 Infection

Brandon A. Guenthart, M.D.,<sup>a</sup> Aravind Krishnan, M.D.,<sup>a</sup> Aiman Alassar, M.D., Ph.D.,<sup>a</sup> Jai Madhok, M.D., M.S.E.,<sup>b</sup> Monika Kakol, M.D.,<sup>c</sup> Shari Miller, PA-C,<sup>a</sup> Sheela Pai Cole, M.D., F.A.S.E.,<sup>b</sup> Vidya K. Rao, M.D.,<sup>b</sup> Natalia Martinez Acero, M.D.,<sup>b</sup> Charles C. Hill, M.D.,<sup>b</sup> Cindy Cheung, M.D.,<sup>b</sup> Ethan C. Jackson, M.D.,<sup>b</sup> Igor Feinstein, M.D., Ph.D.,<sup>b</sup> Albert H. Tsai, M.D.,<sup>b</sup> Joshua J. Mooney, M.D., M.S.,<sup>c</sup> Thomas Pham, M.D.,<sup>d</sup> Irmina A. Elliott, M.D.,<sup>a</sup> Douglas Z. Liou, M.D.,<sup>a</sup> Saverio La Francesca, M.D.,<sup>a</sup> Yasuhiro Shudo, M.D., Ph.D.,<sup>a</sup> William Hiesinger, M.D.,<sup>a</sup> John W. MacArthur, M.D.,<sup>a</sup> Nivaz Brar, M.D.,<sup>e</sup> Gerald J. Berry, M.D.,<sup>e</sup> Matthew B. McCarra, M.D.,<sup>c,f</sup> Tushar J. Desai, M.D.,<sup>c,f</sup> Gundeep S. Dhillon, M.D., M.P.H.,<sup>c</sup> and Y. Joseph Woo, M.D.<sup>a</sup>

From the <sup>a</sup>Department of Cardiothoracic Surgery, Stanford University, Stanford, CA; <sup>b</sup>Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA; <sup>c</sup>Department of Medicine, Division of Pulmonary, Allergy, and Critical Care, Stanford University, Stanford, CA; <sup>d</sup>Department of Surgery, Division of Abdominal Transplantation, Stanford University, Stanford, CA; <sup>e</sup>Department of Pathology, Stanford University, Stanford, CA; and the <sup>f</sup>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA.

#### KEYWORDS:

multi-organ transplant;  
COVID-19, lung  
transplant;  
kidney transplant;  
ECMO

Broad extra-pulmonary manifestations of COVID-19 are being recognized<sup>1</sup>. Notably, SARS-COV-2 has selective kidney tropism, leading to acute kidney injury, found in over 40% of hospitalized patients with COVID-19 in the US<sup>2-4</sup>. Patients who subsequently require dialysis have a poor prognosis with a mortality rate over 75%; among patients who survive to discharge, over 30% will not recover their kidney function and require dialysis<sup>3</sup>.

Patients who recover from severe COVID-19 may be left with end-stage multi-organ dysfunction<sup>5</sup>. There are no reports of kidney or multi-organ transplantation for the treatment of end-stage pulmonary and renal failure due to COVID-19. Herein, we present the first combined lung and kidney transplantation for the successful treatment of end stage pulmonary and renal failure due to COVID-19.

### Case details

A 54-year-old man with no past medical history presented to the emergency department with 5 days of non-productive cough, pleuritic chest pain, and high-grade fevers. He was diagnosed with COVID-19. Within 24 hours of presentation, he required mechanical ventilation and was managed with lung protective ventilation, inhaled pulmonary vasodilators, neuromuscular blockade, and prone positioning. Subsequently, he received remdesivir, methylprednisolone, tocilizumab, and convalescent plasma. On hospital day 18, he required initiation of venovenous-extracorporeal membrane oxygenation (VV-ECMO). By hospital day 21 he developed acute kidney injury requiring continuous renal replacement therapy (CRRT).

Interval chest imaging revealed progressive and near complete bilateral airspace opacification superimposed on diffuse bronchiectasis (Figure 1). Despite aggressive

As the world responds to the global crisis of the COVID-19 pandemic an increasing number of patients are experiencing increased morbidity as a result of multi-organ involvement. Of these, a small proportion will progress to end-stage lung disease, become dialysis dependent, or both. Herein, we describe the first reported case of a successful combined lung and kidney transplantation in a patient with COVID-19. Lung transplantation, isolated or combined with other organs, is feasible and should be considered for select patients impacted by this deadly disease.


J Heart Lung Transplant 000;000:1–4

© 2021 International Society for Heart and Lung Transplantation. All rights reserved.

supportive care, his ARDS progressed to end-stage fibrotic lung disease along with the development of corpulmonale.

He underwent extensive rehabilitation, and at the time of transplantation was neurologically intact and able to sit at the edge of bed for 20 minutes and stand with maximal assist.

The patient was taken to the operating room after suitable donor organs (lungs and kidney) were allocated from a single donor. With on-going ECMO support, the patient



**Figure 1** Serial radiographs from time of presentation and diagnosis (Day 0) to just prior to transplantation (Day 165). Imaging displays progression of disease with increasing bilateral airspace opacities, diffuse consolidation, and air bronchograms. Clinical deterioration necessitating intubation and percutaneous tracheostomy are demonstrated on Day 1 and Day 18 respectively. Maximal medical therapy included the use of lung protective ventilation, inhaled pulmonary vasodilators, neuromuscular blockade, prone positioning, remdesivir, methylprednisolone, tocilizumab, and convalescent plasma. The patient experienced recurrent pneumothoraces requiring multiple bilateral tube thoracostomies (Day 18 – 165). Initiation of veno-venous extracorporeal membrane oxygenation (VV ECMO) occurred on Day 18. The initial strategy of femoro-jugulofemoral (25 Fr femoral drainage, 19 Fr femoral return, 17 Fr internal jugular return) cannulation was later transitioned to a single dual-lumen internal jugular cannula (32 Fr Crescent®; MC3 Cardiopulmonary) to facilitate mobility and rehabilitation on Day 90. The patient remained on VV ECMO for a total of 147 days prior to transplantation.


underwent median sternotomy, cardiopulmonary bypass (CPB) and donor lungs were implanted in standard fashion. The patient was separated from CPB, without the need to re-initiate ECMO support (Supplemental Video 1). Following lung transplantation, the patient remained hemodynamically stable, and 5 hours later, was taken back to the operating room to undergo a deceased donor kidney transplant.

Post-operatively, the patient received standard triple immunosuppressive therapy with tacrolimus, methylprednisolone, and mycophenolate mofetil. Upon discharge to a rehabilitation center, he was on room air with a Cr of 0.42 mg/dL. The patient is now over 90 days post-transplant and recovering well at home. For a complete description of the clinical course, surgical procedure, and pathologic findings please refer to Supplementary Information.

## Discussion


Our experience suggests that in appropriately selected candidates who have exhausted conventional therapeutic options, multi-organ transplantation is both safe and feasible. In the present case, given the patient's radiographic findings of irreversible fibrosis and lack of improvement in pulmonary function despite maximal medical therapy and the prolonged utilization of ECMO, transplantation was the only life-saving intervention available. Histopathologic assessment of the explanted lungs confirmed this clinical assessment (Figures 2-3).

This patient was a suitable candidate for multi-organ transplantation given his relatively young age and lack of significant medical comorbidities prior to COVID-19. Determining transplant candidacy included consideration of standard risk assessment such as age, ability to



**Figure 2** Gross photography of explanted native lungs. (Panel A) Right lung (screen left) and left lung (screen right). Both lungs were small with cobblestoned visceral pleura. (Panel B) Shows the lung is contracted in size with cut surface revealing complete effacement of the pale fibrous tissue and bronchiolectasis of the distal airways.





**Figure 3** Pathological findings in explanted native lungs. (Panel A) Low power magnification showing complete remodeling of the lobules by predominantly fibrous widening of alveolar interstitium and preservation of bronchioles and muscular arteries. Scattered remnants of hyaline membranes are observed undergoing incorporation into the pulmonary interstitium (H&E x100). (Panel B) Higher power magnification (H&E x200). Foci of squamous or bronchiolar metaplasia along with sparse interstitial inflammation and collections of alveolar or hemosiderin-laden macrophages are also present. (Panel C) The Masson's trichrome stain highlights the abundant collagenous fibrosis of the alveolar interstitium (Trichrome x100). (Panel D) Immunohistochemistry (IHC) demonstrating massive expansion of the fibroblast population within the interstitial space as shown by increased vimentin positive cells. E-cadherin labeling of epithelial cells shows abnormal clusters of epithelial cells (asterisk). (Panel E) The distal lung alveolar space is replaced by dense chords of mesenchymal cells with areas with KRT5<sup>+</sup> basal cell layer and overlying ATII (type II pneumocyte) cells staining for HTII-280 (asterisk). (Panel F) B-catenin labeling demonstrating ATII hyperplasia with surfactant protein C (SPC) positive cells demonstrating dysplastic, cord-like growth into the intraluminal space (asterisk). IHC images taken at 20x. Scale bars represent 20µm. For detailed immunohistochemistry methods please refer to Supplementary Information.

participate in rehabilitation, and clinical and radiographic evidence of irreversible disease having allowed for sufficient time for recovery of organ function. In the setting of COVID-19, this case challenges previous recommendations which mandate single organ involvement for transplant candidacy.<sup>6</sup> Confirmation of negative SARS-COV-2 PCR to ensure recovery from COVID-19 is also a necessity when considering single or multi-organ transplantation.<sup>7</sup> At our institution, we perform combined lung and kidney transplantation in a staged approach. Due to the high acuity of combined end-stage pulmonary and renal dysfunction, this approach may be a suitable course for centers considering multi-organ transplantation for patients who have recovered from severe COVID-19 infection.

## Conclusion

With the progression of the COVID-19 pandemic and the high incidence of acute kidney injury in the critically ill subset of infected patients, combined end-stage pulmonary and renal failure will become an increasingly common presentation.<sup>2-4</sup> Our successful use of combined lung and kidney transplantation should serve as cause for consideration for other centers in the treatment of multi-organ failure due to COVID-19.

## Author contributors

BAG, AK, AM, JM, and YJW drafted the report. BAG, AK, JM, MK, SM, SPC, VKR, NMA, CCH, CC, ECJ, IF, AHT, JJM, TP, IAE, DZL, SLF, YS, WH, JWM, GSD, and YJW were involved in the treatment of the patient. BAG, NB, GJB, and YJW acquired, analyzed, and interpreted pathology specimens, histology and radiology images. MBM and TJD performed immunohistochemistry, acquired, and interpreted images. All authors were responsible for critical revision of the manuscript and approved the final version before submission.

## Conflict of interests

The authors have no conflicts of interest related to the subject matter.

## Financial disclosure

The authors received no financial support for the research, authorship, and/or publication of this article.

## Supplementary materials

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.healun.2021.02.015>.

## References

1. Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection. *Clin Exp Med* 2020;20:493-506.
2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020;8:420-2.
3. Chan L, Chaudhary K, Saha A, et al. AKI in Hospitalized Patients with COVID-19. *J Am Soc Nephrol* 2021;32:151-60.
4. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney Int* 2020;98:219-77.
5. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA* 2020;324:782-93.
6. Cypel M, Keshavjee S. When to consider lung transplantation for COVID-19. *Lancet Respir Med* 2020;8:944-6.
7. Doglietto F, Vezzoli M, Gheza F, et al. Factors Associated With Surgical Mortality and Complications Among Patients With and Without Coronavirus Disease 2019 (COVID-19) in Italy. *JAMA Surg* 2020;155:691-702.